Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + CAPOX in Advanced Biliary Tract Carcinoma
NCT03111732Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2017
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in biliary tract carcinoma (BTC), sponsored by National Cancer Institute. Primary endpoint: Progression Free Survival at 5 months. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT03111732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03111732.